sulfotransferase family 2A member 1Genealiases: DHEA-ST · DHEA-ST8 · DHEAS · HST · ST2 · ST2A1
Q-omics provides the consensus-scored SULT2A1 profile across patient tissues and cancer cell-line models. SULT2A1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, SULT2A1 is differentially expressed in 8, with the highest sampling consensus in STAD. Additionally, SULT2A1 RNA expression shows 10,118 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ESCA, STAD, and TGCT as cancer lineages where SULT2A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SULT2A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SULT2A1 survival associations across molecular data types. SULT2A1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SULT2A1 RNA expression–survival associations across cancer types. High SULT2A1 expression shows unfavorable associations in ESCA, KIRC, COAD, MESO and UVM, but favorable associations in LIHC. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ESCA as the clearest survival context for SULT2A1 RNA expression.
This table summarizes SULT2A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for SULT2A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SULT2A1 shows lower tumor expression in STAD, CHOL, LIHC, PRAD and PAAD and higher tumor expression in HNSC. The STAD box plot shows higher SULT2A1 RNA expression in normal versus tumor tissue (log2 FC = −3.085, t-test p = .007).
This table shows molecular features associated with SULT2A1 in patient tissues and cancer cell lines. In patient samples, SULT2A1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SULT2A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LIVER.
